LDN-193189 化学構造
分子量: 406.48





  • Compare TGF-beta/Smad Inhibitors
  • 研究分野



製品説明 LDN-193189は、ALK2ALK3の選択的な阻害剤で、IC50がそれぞれ5 nMと30 nMです。
ターゲット ALK2 ALK3
IC50 5 nM [1] 30 nM [1]
In vitro試験 LDN193189 potently inhibits BMP4-mediated Smad1, Smad5 and Smad8 activation with IC50 of 5 nM, and efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. Furthermore, LDN193189 also shows the inhibitory effect on the transcriptional activity induced by either constitutively active ALK2R206H or ALK2Q207D mutant proteins. [1] A recent study shows that LDN-193189 blocks the production of reactive oxygen species induced by oxidized LDL during atherogenesis in human aortic endothelial cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
C2C12 MUfLbY5ie2ViQYPzZZk> M4i3[IlvcGmkaYTzJJRp\SCtaX7hd4Uh[WO2aY\peJkhd2ZiQVzLOEBidmRiQXP0VmlKSSC5aYToJGlEPTEEoI\hcJVmeyCxZjCxNFEh[W6mIEKxNEBvdSxicnXzdIVkfGm4ZXz5 MojENlU{Pjh|MkK=
EOC216 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;3NE4yNTFyIN88US=> NXL6[YV2Oi1zMDDk M1nreGROW09? M3zjNolv\HWlZTDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVOyOVIzPzh7Mx?=
SKOV3 NFznfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3D[oUzNzVizszN NUjaUmxkPDhiaB?= MXvEUXNQ MUXk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6gV{BxcGG| MVuyOVIzPzh7Mx?=
OVCA429 M2rBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e2NlIwPSEQvF2= NWfWcGRXPDhiaB?= M{LkSWROW09? MlHR[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMheGijcx?= NV3PS3BkOjV{Mke4PVM>
EOC219 M3n1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofpNk82KM7:TR?= Mk\KOFghcA>? NEHkemNFVVOR NEXVclVl\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCyaHHz MW[yOVIzPzh7Mx?=
A549 NVS4b245T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiwMlUuOTZizszN MWHEUXNQ M4nqcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MljrNlQ4PzhyMUG=
BEAS-2B  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HYRVAvPS1zNjFOwG0> MmLySG1UVw>? NILFS2hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHHENJIzPDd5OECxNS=>
hBMSCs MUHGeY5kfGmxbjDBd5NigQ>? MV2wMlLDqM7:TR?= MXO3JIQ> NUfwXph6[WKxbHnzbIV{KHSqZTDzbYxq[mmwaX6tdJJwdW:2ZXSgRWxRKGGldHn2bZR6yqCyYYL0cJk> Mmm2NlQxPzZzOEe=
PANC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXQTHg2NTVyMDDuUS=> MlXFOFghcA>? M37ZbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NInObIozOzl4OUeyPS=>
MIA PaCa-2 M4qweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjVcVc2NTVyMDDuUS=> NGPEOo01QCCq NYK0SG84cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NV3FV|M5OjN7Nkm3Nlk>
Bx-PC3 NFjWelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vETVUuPTByIH7N M{fuOFQ5KGh? MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3X6cFI{QTZ7N{K5
LNCaP M3i3SmZ2dmO2aX;uJGF{e2G7 MYOw5qCUPTByIH7N M{nBVFIhcA>? NF60NlRz\X[ncoPld{Bz[XCjbYnjbY4ucW6mdXPl[EBk\WyuIHTlZZRp M3uxclIzPDV{OEiz
EOC M4faeGZ2dmO2aX;uJGF{e2G7 NGDjdXMyOC1zMECwJI5O NUCyXItuPzJiaB?= NILJeHVz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTl[EBDVVBiUj3TcYFlOS93L{lCpC=> M3\ke|IzOjR7NEG1
HaCaT  NWjYcldsTnWwY4Tpc44hSXO|YYm= MUKwMlAxOS1zMDFOwG0> MonZNkBp NGXWcHFqdmirYnn0d{BDVVB{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPtZYQyNzVxODD3bZRpKGGwIFnDOVDDqG:oII6wMlAxPcLizszN MoP5NlE4PDB7Nk[=
HaCaT  NV3OdmdWTnWwY4Tpc44hSXO|YYm= MorHNE4xODFvMUCg{txO NVTGfXFROiCq MkXPbY5pcWKrdIOgeIhmKGGkaXzpeJkhd2ZiQVzLNkB1dyCyaH;zdIhwenmuYYTlJGdUXC2VbXHkNeKhf2m2aDDhckBKSzVywrDv[kA1PcLibl2= MoryNlE4PDB7Nk[=
HaCaT  MlLaSpVv[3Srb36gRZN{[Xl? MnTMNE4xODFvMUCg{txO M2riWVIhcA>? NGCydFlqdmirYnn0d{B1cGViYXLpcIl1gSCxZjDBUGs{KHSxIIDoc5NxcG:{eXzheIUhW22jZEJCpJdqfGhiYX6gTWM2OMLib3[gNVAxKG6P MVOyNVc1ODl4Nh?=

... Click to View More Cell Line Experimental Data

In vivo試験 In conditional caALK2-transgenic mice with Ad.Cre on on postnatal day 7 (P7), LDN-193189 (3 mg/kg i.p) leads to mild calcifications surrounding the left tibia and fibula first visible at P13, and prevents radiographic lesions at P15 without causing weight loss or growth retardation, spontaneous fractures, decreased bone density or behavioral abnormalities. [1] LDN193189 dorsalizes zebrafish embryos by inhibiting signaling pathways induced by bone morphogenetic protein (BMP)6 without effect on vascular development. [2] In PCa-118b tumor-bearing mice, LDN-193189 treatment attenuates tumor growth and reduces bone formation in the tumors. [3] In LDL receptor-deficient (LDLR-/-) mice, LDN-193189 potently inhibits development of atheroma. Moreover, LDN-193189 also exhibits the inhibitory effects on associated vascular inflammation, osteogenic activity, and calcification. [4]

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Alkaline phosphatase activity C2C12 cells are seeded into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. The wells are treated in quadruplicate with BMP ligands and LDN-193189 or vehicle. The cells are collected after 6 days in culture in 50 μL Tris-buffered saline and 1% Triton X-100. The lysates are added to p-nitro-phenylphosphate reagent in 96-well plates for 1 hours and then evaluated alkaline phosphatase activity (absorbance at 405 nm). Cell viability and quantity are measured by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements.

動物実験: [1]

動物モデル Ad.Cre on P7 is injected into conditional caALK2–transgenic and wild-type mice.
製剤 LDN193189 is dissolved in DMSO and then diluted in water.
投薬量 ≤3 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download LDN-193189 SDF
分子量 406.48


CAS No. 1062368-24-4
保管 3年-20℃
2年-80℃in solvent
別名 DM3189
溶解度 (25°C) * In vitro Ethanol 1 mg/mL warming (2.46 mM)
DMSO <1 mg/mL
Water <1 mg/mL
In vivo Saline (suspension) 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline

文献中の引用 (12)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related TGF-beta/Smad 阻害剤

  • SD-208

    SD-208は1種のセレクティブTGF-βRI (ALK5)阻害剤です。このIC50値は48 nMです。選択性について、TGF-βRI (ALK5)はTGF-βRIIより100倍以上が高くなります。

  • LDN-214117

    LDN-214117は1種の有効的でセレクティブBMP I型受容体キナーゼALK2阻害剤です。このIC50値は24 nMです。

  • SB431542

    SB431542 は ALK5を抑制する時IC50が94 nMになる.

  • Galunisertib (LY2157299)

    Galunisertib (LY2157299)は、強力なTβRIとTβRII(トランスフォーミング成長因子βレセプターIおよびII)阻害剤で, IC50がそれぞれ86 nM と 2 nMです。

  • SB525334

    SB525334 は有効な選択を転化成長因子-β1(TGF -β1)受容体(活性化素受容体類キナーゼ5、ALK5)、IC50 が14.3 nMになる.

  • LY2109761

    LY2109761は、新しい選抜TGFβレセプター・タイプIとタイプII(TβRI/II)二重阻害剤で、 Ki がそれぞれ38 nM と 300 nMになる。

  • RepSox

    RepSox is a potent and selective inhibitor of the TGFβ/ALK5 with IC50 of 23 nM.

  • Pirfenidone

    Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, also reduces production of TNF-α and IL-1β, has anti-fibrotic and anti-inflammatory properties. Phase 3.

  • DMH1

    DMH1は1種のセレクティブBMP受容体阻害剤で、ALK2を抑制します。このIC50値は107.9 nMになります。尚、DMH1はAMPK、 ALK5、KDR (VEGFR-2)とPDGFRに抑制効果を与えません。


Tags: LDN-193189を買う | LDN-193189供給者 | LDN-193189を購入する | LDN-193189費用 | LDN-193189生産者 | オーダーLDN-193189 | LDN-193189代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID